Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology

Protein; Disease Clinical Trial

Official title:

Pilot Study on Proteomics of Erythrocyte Proteins in Patients With Chronic Obstructive Pulmonary Disease Based on TMT Technology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05376618
• Other study ID #: 2021-KY-060--01
• Status: Completed
• Start date: July 15, 2021
• Est. completion date: July 15, 2022

Study information

• Verified date: July 2021
• Source: Zhujiang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition. Further investigations on the cellular and molecular aspects of hypoxia in COPD should help to reveal the mechanisms underlying the development of this disease. Dysfunction of the erythrocyte, a main medium to transport oxygen through the blood, contributes to the prognosis and severity of COPD through hypoxia. It is proposed that dysregulated proteins in erythrocytes that impair oxygen transport may be involved in the development of COPD. However, a comprehensive study on altered proteins of erythrocytes in COPD is still lacking. Proteomics techniques and protein chip techniques provide a high throughput screening method to figure out characteristic inflammatory or metabolic markers of diseases. Therefore, this study is to evaluate the clinical significance of differential erythrocyte proteins in the course of COPD disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 15, 2022
• Est. primary completion date: July 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

1. case group

Inclusion Criteria:

1. Age from 40 to 80 years old; gender is not limited.

2. Stable COPD

3. Sign the informed consent with the willingness of obeying the protocol. -

Exclusion Criteria:

1. Subjects with known other chronic respiratory diseases except for COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);

2. Subjects had been accepted lung lobectomy or transplantation;

3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );

4. Alcoholism, drug or solvents addition;

5. Acute exacerbation COPD patients (AECOPD) -

2. control group Inclusion criteria

1. Age from 40 to 80 years old; gender is not limited.

2. Sign the informed consent with the willingness of obeying the protocol. - Exclusion criteria

1. Subjects with known other chronic respiratory diseases (such as COPD, asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);

2. Subjects had been accepted lung lobectomy or transplantation;

3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );

4. Alcoholism, drug or solvents addition;

Related Conditions & MeSH terms

• Protein; Disease

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	Zhujiang Hospital,Southern Medical Universtiy	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Protein biomarkers in erythrocyte predicting rapid decline of lung function	The study is to identify the biomarkers and make sure which is associated with rapid decline of lung function. The study will include a total of 30 study subjects.	2021-7-15 to 2022-7-15